Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10166349 | 0.94 | BRAF (0.42) | CD274AURKAAURKBHPGDMAPK14 | |
| SCHEMBL10166145 | 0.94 | BRAF (0.42) | CD274HPGDMAPK14 | |
| SCHEMBL10165789 | 0.90 | NAMPT (0.39) | HPGD | |
| SCHEMBL10166155 | 0.88 | TTK (0.35) | MAPKAPK5 | |
| SCHEMBL10166358 | 0.87 | BRAF (0.38) | AURKAAURKBMAPK14MAPKAPK5 | |
| SCHEMBL10166838 | 0.86 | FYN (0.45) | AURKAAURKBMAPK14 | |
| SCHEMBL10166351 | 0.86 | MAPKAPK5 (0.43) | MAPKAPK5 | |
| SCHEMBL1685166 | 0.86 | MAPKAPK5 (0.55) | CD274HPGDSAURKAAURKBHPGD | |
| SCHEMBL10166148 | 0.85 | POLB (0.40) | — | |
| SCHEMBL10166840 | 0.85 | FYN (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | CD274 2609/4885HPGDS 49/4885AURKA 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.